Some of the most accomplished clinicians and pioneering investigators are devoting themselves to the battle against TK2 deficiency.
MICHIO HIRANO, M.D.
Dr. Hirano, Professor of Neurology at Columbia University Medical Center, is Director of the H. Houston Merritt Clinical Research Center. He received his M.D. from the Albert Einstein College of Medicine, did his internship at the affiliated Bronx Municipal Medical Center, and his Neurology Residency at Columbia-Presbyterian Medical Center. Since 1992, Dr. Hirano has been on the faculty of Columbia, where he conducts transnational research on neuromuscular disorders with a special focus on mitochondrial diseases. As principal investigator on several NIH and private foundation grants, he has identified the causative genes for several inherited diseases, with the use of cultured cells and mouse models.
SALVATORE DiMAURO, M.D.
Dr. Di Mauro is Lucy G. Moses Professor of Neurology, and Director Emeritus of the H. Houston Merritt Clinical Research Center. Throughout his career, Dr. DiMauro had kept a focused interest on inborn errors of energy metabolism, recognizing unusual patients through clinical observation, and using both biochemical and molecular approaches to define disease entities. At Columbia, he set up biochemical tests to study respiratory chain enzymes in frozen muscle biopsies, which were sent from all over the world. His work has been internationally recognized, gathering awards not just in the U.S., but from the most prominent medical organizations in France, Spain and his native Italy.
CATERINA GARONE, M.D.
Dr. Garone, a pediatric neurologist, is currently a postdoctoral research scientist in mitochondrial disorders in the laboratories of Drs. Salvatore DiMauro and Michio Hirano, as well as a Ph.D. student in Human Genetics in the Joint Program of the Universities of Bologna and Turin. She brings both clinical expertise and research experience to her work as part of the TK2 team, with extensive knowledge with regard to historiology and molecular genetics. Most recently, she has been testing a novel therapy for TK2 deficiency in a mouse model in Dr. Hirano's laboratory.